ArticleArchives of microbiology2026
Evaluation of the antibacterial activity of stem cells from apical papilla and their conditioned medium against Escherichia coli and Staphylococcus aureus.
Article in Archives of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human mesenchymal stem cells (hMSCs) are versatile cells obtained from various regions of the human body. Beyond their potential for cell replacement, MSCs secrete a wide range of growth factors and cytokines and have recently been recognized for their potent antibacterial activity, representing a promising approach to combat bacterial infections. This study is the first to evaluate the antibacterial properties of stem cells from apical papilla (SCAPs) and their conditioned medium (CM) against Staphylococcus aureus (S. aureus) and Escherichia coli (E. coli) using colony count and disk diffusion assays. The minimum inhibitory and bactericidal concentrations were determined through serial dilutions of SCAP-CM, and the expression of antibacterial and immunomodulatory genes was analyzed by qRT-PCR. Both SCAPs and human foreskin fibroblasts (HFFs) exhibited antibacterial activity, as shown by CFU and disk diffusion assays, with SCAP-CM demonstrating greater efficacy. The minimum bactericidal concentrations of SCAP-CM against E. coli and S. aureus were 2.5 mg/ml for both, compared to 80 mg/ml and 320 mg/ml for HFF-CM, respectively. SCAPs showed increased expression of antibacterial and immunomodulatory genes in response to both bacterial strains, whereas HFFs displayed reduced IL1β and variable changes in IL6 and TNFα depending on the strain. The antibacterial effect was partially attributed to secretion of the LL-37 peptide. These findings confirm SCAPs exhibit potent antibacterial activity against both Gram-negative and Gram-positive bacteria, mediated by soluble immunoregulatory factors, with inhibitory effects comparable to gentamicin and distinct from those of HFFs. They provide mechanistic insight into SCAP-derived antimicrobial responses and highlight their potential as antibiotic-sparing therapeutic strategies.
Indexed as
Identifiers
42176067What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.